07.07.2014 Views

final report - ARCHIVE: Defra

final report - ARCHIVE: Defra

final report - ARCHIVE: Defra

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

5 VACCINES<br />

5.1 Current and recent research<br />

5.1.1 The Krebs Report (Krebs et al., 1997) stated that ‘In the long run, the best prospect for control of<br />

bovine TB is to develop a vaccine for cattle. This is a long-term (more than ten years) strategy and<br />

success cannot be guaranteed. However, targets and milestones can be identified to monitor and<br />

evaluate progress at five yearly intervals. We recommend that the development of a cattle vaccine and<br />

an associated diagnostic test to distinguish infected from vaccinated cattle should be a high priority for<br />

MAFF’s long-term research strategy. A badger vaccine, although posing greater technical problems in<br />

terms of both development and delivery, should also be kept as an option. During the next five years<br />

much of the basic research required will be relevant to both badgers and cattle’.<br />

5.1.2 Against this background, the <strong>Defra</strong> programme of research, supported by underpinning BBSRC<br />

projects, has the following overall aims:<br />

<br />

To demonstrate a near-term option for the vaccination of cattle;<br />

<br />

To demonstrate a near-term option for the vaccination of badgers;<br />

<br />

To identify candidate next-generation improved vaccines for use in cattle.<br />

Where appropriate, we have also considered work outside of the <strong>Defra</strong> programme and which could support<br />

the aims outlined in the Krebs Report.<br />

5.1.3 The <strong>Defra</strong> programme on vaccines includes work to devise vaccines for use in badgers or in cattle.<br />

Project SE3223 is a critical element of the programme and involves devising a formulation of BCG<br />

suitable for use in badgers. As part of this programme, the safety of the formulated vaccine in badgers<br />

will be determined. Project CB0116 will carry out more detailed efficacy testing of candidates in wild<br />

badgers. These projects build on project SE3228 (completed), which demonstrated the safety and<br />

immunogenicity of BCG in badgers. A more detailed study to investigate safety, immunogenicity and<br />

lack of shedding following the immunization of wild badgers with BCG is under way (CB0115).<br />

37

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!